ProQR Therapeutics - Stock Price History | PRQR

Historical daily share price chart and data for ProQR Therapeutics since 2021 adjusted for splits. The latest closing stock price for ProQR Therapeutics as of September 27, 2021 is 7.55.
  • The all-time high ProQR Therapeutics stock closing price was 24.99 on March 10, 2015.
  • The ProQR Therapeutics 52-week high stock price is 9.46, which is 25.3% above the current share price.
  • The ProQR Therapeutics 52-week low stock price is 3.40, which is 55% below the current share price.
  • The average ProQR Therapeutics stock price for the last 52 weeks is 5.55.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
ProQR Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.6152 9.9000 9.9000 3.5800 4.2000 -57.62%
2019 10.5704 17.4800 18.4800 5.7600 9.9100 -37.20%
2018 9.3425 3.3000 22.4000 2.9000 15.7800 389.30%
2017 4.5380 4.9000 6.4500 2.8000 3.2250 -34.18%
2016 5.2225 7.7300 7.7300 3.6400 4.9000 -43.55%
2015 16.8812 20.4600 24.9900 6.9700 8.6800 -59.94%
2014 15.2818 14.7300 21.6700 11.4400 21.6700 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.379B $0.011B
ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29